This is a textbook strong insider buy cluster: a 10% owner and the entire C-suite buying simultaneously at a 7% discount to the prior day's close ($1.65 vs $1.53). The 2.4% of market cap deployed is well above the 2% materiality threshold. Traders should watch for a potential catalyst (pipeline update, partnership, or financing) given the coordinated nature. The historical calibration shows cluster buys at this magnitude have a 57% win rate at T+20 with +38.6% mean alpha on wins, though the segment's average net alpha is -0.61% after costs — suggesting a strong but not guaranteed setup.
Price Chart
Executive Summary
A powerful insider buying cluster at Camp4 Therapeutics: 5AM Partners VI (a 10% owner) made a $4.86M open-market purchase at $1.53/share, while the CEO, CFO, CMO, and a director each bought ~$11K-$27K at $1.65 on the same day. The total $4.92M in open-market buys represents ~2.4% of the $208M market cap, a highly material signal. This cluster is amplified by the presence of both a large-block owner and the entire C-suite acting in concert, which historically carries strong predictive power for positive returns.
Key Financial Metrics
Key Facts
- 5AM Partners VI, LLC purchased 3.18M shares for $4.86M in a single open-market transaction.
- CEO, CFO, CMO, and a director each bought ~$11K-$27K at $1.65/share on the same day.
- Total cluster value of $4.92M equals ~2.4% of CAMP's $208M market cap.
- The CEO, CFO, and CMO all bought identical 6,551-share amounts, suggesting coordinated insider conviction.
- No 10b5-1 plan pattern detected; all purchases are open-market and clustered on one date.
Financial Impact
Insider cluster of $4.92M in open-market purchases, representing 2.4% of market cap — a highly material signal of insider conviction.
Risk Factors
- The 5AM Partners purchase at $1.53 was a grant/award (code A) to director Schwab, not a pure open-market buy — the economic signal is that 5AM funded the grant, but the transaction structure is non-cash for the recipient.
- CAMP is a pre-revenue biotech with high binary risk; insider buys cannot de-risk clinical trial outcomes.
- Historical T+20 win rate on CAMP reports is only 44%, suggesting the stock has been volatile and hard to predict.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CAMP-1786004121772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $4.34 $4.03 | ▼ −7.14% | ▼ −6.64% | $3.73 (−13.95%) |
Sep 2, 2026 29d ago | Insider Cluster | $4.49 $4.25 | ▼ −5.35% | ▼ −4.20% | $3.73 (−16.83%) |
Aug 21, 2026 6w ago | Insider Cluster | $4.48 $4.15 | ▲ +7.37% | ▲ +7.84% | $3.73 (+16.64%) |
Aug 13, 2026 7w ago | EFFECT | $4.50 $4.45 | ▼ −1.11% | ▲ +0.85% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Jul 27, 2026 9w ago | 8-K | $3.42 $3.45 | ▲ +0.88% | ▼ −0.20% | $3.73 (+9.20%) |
Jun 19, 2026 14w ago | Press Release | $4.20 $4.20 | · 0.00% | ▲ +2.07% | $3.73 (−11.08%) |
Jun 12, 2026 15w ago | 8-K | $3.96 $4.20 | ▲ +6.06% | ▲ +7.44% | $3.73 (−5.69%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.22 $4.14 | ▼ −1.90% | ▼ −2.33% | $3.73 (−11.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access